Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral… (NCT01662856) | Clinical Trial Compass
CompletedPhase 3
Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery
United States225 participantsStarted 2012-08
Plain-language summary
The purpose of this study is to demonstrate that the application of Fibrin Sealant Grifols provides a measurable benefit when compared to hemostasis achieved through conventional surgical technique (suture) and by standard hemostatic action, such as mechanical pressure through manual compression. This study has a Preliminary Part (I) in which all subjects are treated with Fibrin Sealant Grifols and a Primary Part (II) in which subjects are randomized in a 2:1 ratio to either Fibrin Sealant Grifols or manual compression.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Hemoglobin (Hgb) ≥ 8.0 g/dL at Baseline (within 24 hours prior to surgical procedure).
* Require elective (non-emergency), primary, open (non-laparoscopic; non-endovascular) peripheral vascular surgery.
* Require one of the following peripheral vascular procedures involving proximal end-to-side arterial anastomosis utilizing coated or uncoated Polytetrafluoroethylene grafts: a) Femoral-femoral bypass grafting, b) Femoral-popliteal bypass grafting, c) Femoral-distal bypass grafting, d) Ilio-iliac bypass grafting, e) Ilio-femoral bypass grafting, f) Ilio-popliteal bypass grafting, g) Aorto-iliac bypass grafting, h) Aorto-femoral bypass grafting, i)Axillo-femoral bypass grafting, and j) Upper extremity vascular access for hemodialysis.
* A target bleeding site can be identified.
* Target bleeding site has moderate arterial bleeding.
Exclusion Criteria:
* Undergoing a re-operative procedure.
* Undergoing other vascular procedures during the same surgical session (stenting and/or endarterectomy of the same artery are allowed).
* Have an infection in the anatomic surgical area.
* Have a history of severe (e.g. anaphylactic) reactions to blood or to any blood-derived product.
* Have previous known sensitivity to any Fibrin Sealant Grifols, heparin, or protamine component.
* Females who are pregnant or nursing a child at Baseline (within 24 hours prior to surgical procedure).
* Have undergone a therapeutic surgical procedure within 30 days from the screening …
What they're measuring
1
Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start
Timeframe: From start of treatment until 4 minutes after treatment start